Detlef Degner

Detlef Degner

Auto-generated profile, based on publicly available information

Detlef Degner

Department of Psychiatry and Psychotherapy, University of Göttingen, D-37075 Göttingen, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2014 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
DDDetlef Degner
Detlef Degner
MHMerle Haust
Merle Haust
JMJohannes Meller
Johannes Meller
EREckart Rüther
Eckart Rüther
URUdo Reulbach
Udo Reulbach

23 March 2011 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Open access
PDF file
DDDetlef Degner
Detlef Degner
MNMichael A. Nitsche
Michael A. Nitsche
FBFrank Bias
Frank Bias
EREckart Rüther
Eckart Rüther
URUdo Reulbach
Udo Reulbach
The aim of this naturalistic observational study was to investigate EEG alterations in patients under olanzapine treatment with a special regard to olanzapine dose and plasma concentration. Twenty-two in-patients of a psychiatric university ward with the monodiagnosis of paranoid schizophrenia (ICD-10: F20.0), who received a monotherapy of olanzapine were included in this study. All patients had a normal alpha-EEG before drug therapy, and did not suffer from brain-organic dysfunctions, as verified by clinical examination and cMRI scans. EEG and olanzapine plasma levels were determined under steady-state conditions (between 18 and 22 days after begin of treatment). In 9 patients (40.9%), pathological EEG changes (one with spike-waves) consecutive to olanzapine treatment were observed. The dose of olanzapine was significantly higher in patients with changes of the EEG than in patients without changes (24.4 mg/day (SD: 8.1) vs. 12.7 mg/day (SD: 4.8); T = −4.3, df = 21, P < 0.001). In patients with EEG changes, the blood plasma concentration of olanzapine (45.6 μg/l (SD: 30.9) vs. 26.3 μg/l (SD: 21.6) tended to be also higher. The sensitivity of olanzapine dosage to predict EEG changes was 66.7%, the specificity 100% (Youden-index: 0.67). EEG abnormalities during olanzapine treatment are common. These are significantly dose dependent. Thus, EEG control recordings should be mandatory during olanzapine treatment with special emphasis on dosages exceeding 20 mg per day, although keeping in mind that EEGs have only a limited predictive power regarding future epileptic seizures.

1 October 2000 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
DDDetlef Degner
Detlef Degner
SBStefan Bleich
Stefan Bleich
RGRenate Grohmann
Renate Grohmann
BBBorwin Bandelow
Borwin Bandelow
EREckart Ruther
Eckart Ruther

1 May 2000 in The Journal of Neuropsychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
DDDetlef Degner
Detlef Degner
SBStefan Bleich
Stefan Bleich
PMPeter Müller
Peter Müller
GHGöran Hajak
Göran Hajak
LALothar Adler
Lothar Adler
EREckart Rüther
Eckart Rüther

24 March 2015 in BMJ
Verified
Journal Article
Closed access
PDF file
DDDetlef Degner
Detlef Degner
Over the past 20 years the use of second generation antipsychotics has shifted from schizophrenia to affective disorders. Pringsheim and colleagues described the benefits and risks of quetiapine as adjunctive treatment in major depressive disorder.1 However, they did not mention some …

18 July 2005 in Pharmacopsychiatry
Verified
Journal Article
Closed access
DDD. Degner
D. Degner
SKS. Kropp
S. Kropp
JPJ. Porzig
J. Porzig
RGR. Grohmann
R. Grohmann
ERE. Rüther
E. Rüther
The goal of the multicenter drug surveillance project AMSP (”Arzneimittelsicherheit in der Psychiatrie”) is the monitoring, assessment and analysis of adverse drug reactions (ADR) of psychopharmalogical drugs. We report about a 23 year-old patient with a depressive episode. He developed severe pseudohallucinations under a treatment with moclobemide. The symptoms occur 6 days after starting the medication and decline within two days after stopping moclobemide. The term "pseudohallucinations" is discussed controversially but still of high interest.